99mTc-3P-RGD2 has been used to monitor the tumor response to antiangiogenesis treatment with linifanib (ABT-869) (Ji et al. 2013b, d), a multi-targeted receptor tyrosine kinase inhibitor targeting vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptors (Albert et al. 2006; Shankar et al. 2007; Wong et al. 2009; Zhou et al. 2009; Hernandez-Davies et al. 2011; Jiang et al. 2011; Tannir et al. 2011; Luo et al. 2012). Here, VEGFA is linked to neoplasm.